Edit |   |
---|---|
Antigenic Specificity | CD279, Human (Camrelizumab biosimilar) |
Clone | Camrelizumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | ELISA, IHC, IF, IP, FCM, Block |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human CD279 Recombinant Antibody (Camrelizumab). Camrelizumab (SHR-1210) (INN) is an anti-PD-1 immune checkpoint inhibitionitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials. |
Immunogen | n/a |
Other Names | Anti-CD279 Recombinant Antibody, Research Grade Camrelizumab, Anti-Human CD279 Recombinant Antibody(Camrelizumab), SHR-1210, Antibody Drug Analogues, Monoclonal Antibody, YR1436, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1798286-48-2 |
Catalog # | YR1436 |
Price | please inquire |
Order / More Info | CD279, Human (Camrelizumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |